Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

242
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
242
Cancer02:18

Cancer

53.7K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.7K
What is Cancer?02:12

What is Cancer?

14.0K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.0K
Cancer Prevention02:59

Cancer Prevention

7.7K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.7K
Cancer Therapies02:49

Cancer Therapies

9.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Cancer Vaccines01:30

Cancer Vaccines

984
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
984

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Breast (Edinburgh, Scotland)·2026
Same author

Cancer in a drop: Liquid biopsy highlights from the San Antonio Breast Cancer Symposium (SABCS) 2025.

The journal of liquid biopsy·2026
Same author

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study.

Molecular oncology·2026
Same author

Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025.

Cancer·2026
Same author

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.

Science translational medicine·2026
Same author

Quantitative HER2 profiling on circulating tumor cells using an EpCAM-independent platform in metastatic breast cancer.

Cancer cell international·2025

Related Experiment Video

Updated: Jan 22, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

Biosimilars for breast cancer.

Bruna Migliavacca Zucchetti1,2, Eleonora Nicolò1,3, Giuseppe Curigliano1,3

  • 1Division of Early Drug Development for Innovative Therapy, European Institute of Oncology IRCCS , Milan , Italy.

Expert Opinion on Biological Therapy
|June 29, 2019
PubMed
Summary
This summary is machine-generated.

Biosimilars offer a cost-effective alternative to biologic cancer drugs like trastuzumab, improving access to treatment for breast cancer (BC) patients. These biosimilar drugs demonstrate similar efficacy and safety to reference biologics.

Keywords:
Biologic agentsHER2 amplified breast cancerbiosimilarstrastuzumab

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.9K
Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
10:51

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Published on: April 23, 2021

4.6K

Related Experiment Videos

Last Updated: Jan 22, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.9K
Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
10:51

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Published on: April 23, 2021

4.6K

Area of Science:

  • Oncology
  • Pharmacoeconomics

Background:

  • Biologic agents, such as trastuzumab, have revolutionized breast cancer (BC) treatment, significantly improving patient survival.
  • High costs of biologic therapies pose challenges to healthcare systems globally, limiting patient access.
  • Biosimilars are emerging as a cost-effective alternative to reference biologics, aiming to reduce healthcare expenses.

Purpose of the Study:

  • To review the development and current use of biosimilars for breast cancer (BC).
  • To focus on trastuzumab biosimilars and their role in improving patient access to monoclonal antibodies.

Main Methods:

  • Literature review using MEDLINE/PubMed.
  • Analysis of FDA and EMA statements on biosimilars.

Main Results:

  • Biosimilars exhibit comparable efficacy, safety, and immunogenicity to reference biologic products.
  • Estimated production cost savings of 20-30% for biosimilars compared to reference biologics.
  • Biosimilars are increasingly integrated into clinical practice.

Conclusions:

  • Biosimilars represent a significant advancement in making advanced cancer therapies more accessible.
  • The lower cost of biosimilars is expected to alleviate financial burdens on healthcare systems and patients.
  • Continued development and adoption of biosimilars hold promise for broader patient access to essential treatments.